BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Trending Topics in ADME & Drug Development Research, a ...

Earlier in his career, Mr. Russo worked in roles of increasing responsibility within Merck & Co., Inc.'s manufacturing ... from the University of Chicago Booth School of Business, and he is ...

Chengdu InSiGa Semiconductor Technologies Co., Ltd. ("InSiGa") and POET Technologies Inc. ("POET") , today announced that they have developed and will showcase in a live demonstration the combination ...

Winners will be featured in the VETTY Awards booth inside the Expo Hall and receive an invitation ... Kit" by Boehringer ...

Dehydration in children. In Merck Manual Professional Version. Merck & Co., Inc. 2023. Edmonds CJ, Foglia E, Booth P, Fu CHY, Gardner M. Dehydration in older people: a systematic review of the effects ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers. The FDA approves MRK's Keytruda for first-line ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...